350K+
Sudden cardiac deaths per year in U.S.
$17B
Annual U.S. burden from VA readmissions
$50K
Added costs per patient
0
Preventive options for arrhythmia
The Challenge
Current Therapies Fall Short
Current ventricular arrhythmia therapies rely on rigid leads that provide incomplete coverage and fail to treat deep scarred myocardium.
Incomplete Conduction
Rigid leads cannot reach deep myocardial scar tissue, leaving re-entry circuits untreated.
Economic Burden
Readmissions and corrective procedures drive significant costs for health systems.
Painful Therapy
High-energy shocks that exceed pain thresholds are required to compensate for poor coverage, causing PTSD and severe patient pain.
Our Solution
Injectable Electrode System
The first device to prevent ventricular arrhythmias by forming a stable, conductive "highway" through the venous system to reach deep myocardial tissue.
1
Biostable & Conductive
Our hydrogel material is biostable, elastic, hemocompatible, and conductive, enabling efficient electrical stimulation across tissue with long-term stability.
2
Deep Myocardium Access
Our hydrogel creates a continuous conductive path deep into the myocardium, enabling low-energy cardiac stimulation and defibrillation previously impossible with rigid leads.
3
Physiologic Pacing
By capturing deep septal bundle branches, we restore native-like QRS morphology, improving therapeutic effectiveness while reducing procedural complexity.
4
Minimally Invasive
Seamless integration with existing pacemaker/ICD ecosystems and clinical workflow. No open-heart surgery required.
Regulatory Milestone
Breakthrough Device Designation
Rhythio was awarded FDA Breakthrough Device Designation in October 2025, validating the significant unmet need and the potential of our technology. We are guided through the PMA Class III clearance pathway with a robust IP portfolio covering hydrogel-mediated pacing, ablation, and catheter designs. Preclinical efficacy and safety have been demonstrated in large animal models.
Peer-Reviewed Science
Published Research
Our technology is backed by rigorous preclinical research published in leading scientific journals.
Nature Communications
Rodriguez-Rivera et al., 2024
Demonstrates successful deployment in a porcine model, achieving QRS morphology comparable to native sinus rhythm and capturing deep septal bundle branches.
Biomaterials
Rodriguez-Rivera et al., 2025
Details the PEUDAm macromer design, confirming hydrolytic resistance, biocompatibility, and ionic conductivity retention in vivo.
Leadership
Founding Team
World-class expertise in cardiovascular devices, biomaterials, and clinical electrophysiology.
Advisors
Industry veterans and successful entrepreneurs guiding our path to market.